$2.33
Today
as of Aug 5, 16:55 ET
Last 30 days
Recent Press Releases & News
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
Overview
52-week range
$2.05
$7.40
5% of range
Avg surprise (last 3)
+30.2%
Avg reaction (last 2)
+1.8%
50% positive
Latest IV / EM
274%
EM ±34.3% · $3 · Aug 14
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 13, 2026 | Mar/2026 | $-0.13 | $-0.37 | +64.9% | -160.0% | -0.4% | earnings |
| Tue Aug 12, 2025 | Jun/2025 | $-0.50 | $-0.55 | +9.1% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.05 | $-0.06 | +16.7% | — | +4.0% | earnings |
| Sun Mar 31, 2024 | Mar 2024 | $-0.07 | — | — | — | — | financials |
| Sun Dec 31, 2023 | Dec 2023 | $-0.08 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.08 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | BMO | -$0.34 | -$0.50 | +32.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | $3M |
| Gross profit | — | — | — | — | — | — | — | $1M |
| Operating income | $-7M | $-5M | — | $-8M | $-8M | $-10M | — | $-11M |
| Net income | $-3M | $-5M | — | $-7M | $-8M | $-9M | — | $-11M |
| EPS (diluted) | — | — | — | — | — | — | — | — |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $28M | $33M | $16M | $15M | $20M | $27M | $25M | $29M |
| Inventory | — | — | — | — | — | — | — | $5M |
| Total current assets | $33M | $37M | $19M | $16M | $21M | $28M | $35M | $38M |
| Total assets | $43M | $48M | $30M | $27M | $33M | $40M | $60M | $65M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $8M | $10M | $12M | $12M | $12M | $13M | $28M | $27M |
| Total equity | $35M | $37M | $18M | $15M | $21M | $27M | $32M | $38M |